JP2016535787A - 新規方法 - Google Patents

新規方法 Download PDF

Info

Publication number
JP2016535787A
JP2016535787A JP2016552485A JP2016552485A JP2016535787A JP 2016535787 A JP2016535787 A JP 2016535787A JP 2016552485 A JP2016552485 A JP 2016552485A JP 2016552485 A JP2016552485 A JP 2016552485A JP 2016535787 A JP2016535787 A JP 2016535787A
Authority
JP
Japan
Prior art keywords
compound
formula
treated
edema
aquaporin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016552485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016535787A5 (enExample
Inventor
マーク・エフ・ペレティエ
ポール・ロバート・マクガーク
ジョージ・ウィリアム・ファー
スティーブン・ウィリアムズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeromics Inc
Original Assignee
Aeromics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeromics Inc filed Critical Aeromics Inc
Publication of JP2016535787A publication Critical patent/JP2016535787A/ja
Publication of JP2016535787A5 publication Critical patent/JP2016535787A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
JP2016552485A 2013-11-06 2014-11-06 新規方法 Ceased JP2016535787A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361900946P 2013-11-06 2013-11-06
US201361900919P 2013-11-06 2013-11-06
US201361900878P 2013-11-06 2013-11-06
US61/900,946 2013-11-06
US61/900,919 2013-11-06
US61/900,878 2013-11-06
PCT/US2014/064432 WO2015069948A1 (en) 2013-11-06 2014-11-06 Novel methods

Publications (2)

Publication Number Publication Date
JP2016535787A true JP2016535787A (ja) 2016-11-17
JP2016535787A5 JP2016535787A5 (enExample) 2017-12-14

Family

ID=53042097

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016552485A Ceased JP2016535787A (ja) 2013-11-06 2014-11-06 新規方法
JP2016552486A Active JP6535338B2 (ja) 2013-11-06 2014-11-06 新規製剤
JP2019102367A Active JP6957557B2 (ja) 2013-11-06 2019-05-31 新規製剤
JP2021164647A Pending JP2022003084A (ja) 2013-11-06 2021-10-06 新規製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016552486A Active JP6535338B2 (ja) 2013-11-06 2014-11-06 新規製剤
JP2019102367A Active JP6957557B2 (ja) 2013-11-06 2019-05-31 新規製剤
JP2021164647A Pending JP2022003084A (ja) 2013-11-06 2021-10-06 新規製剤

Country Status (14)

Country Link
US (9) US20160279155A1 (enExample)
EP (3) EP3065729A4 (enExample)
JP (4) JP2016535787A (enExample)
KR (1) KR20160079109A (enExample)
CN (3) CN106163506A (enExample)
AU (2) AU2014346682B2 (enExample)
CA (1) CA2929821A1 (enExample)
ES (1) ES2834131T3 (enExample)
HK (1) HK1224228A1 (enExample)
IL (1) IL245420B (enExample)
MX (2) MX386250B (enExample)
RU (1) RU2691951C2 (enExample)
SG (1) SG11201604153UA (enExample)
WO (3) WO2015069956A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021023226A (ja) * 2019-08-06 2021-02-22 学校法人慶應義塾 アクアポリン活性調節剤候補のハイスループットスクリーニング方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014027983B1 (pt) 2012-05-08 2022-05-24 Aeromics, Inc Uso de inibidores de aquaporina seletivos
RU2691951C2 (ru) 2013-11-06 2019-06-19 Аэромикс, Инк. Новые составы
AU2017261828B2 (en) * 2016-05-13 2023-04-13 Aeromics, Inc. Crystals
CN110790787B (zh) * 2019-11-12 2022-06-14 广东药科大学 一类水溶性前药、其制备方法及其作为药物的用途
MX2023001493A (es) * 2020-08-05 2023-06-23 Jiangsu Simcere Pharm Co Ltd Composicion farmaceutica de un inhibidor de la acuaporina y metodo para la preparacion de la misma.
CN117105810B (zh) * 2023-10-23 2024-02-09 中国农业大学 一种具有广谱抗菌活性的化合物及其抗菌组合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003103656A1 (ja) * 2002-06-06 2003-12-18 株式会社医薬分子設計研究所 Ｏ−置換ヒドロキシアリール誘導体
WO2003103654A1 (ja) * 2002-06-10 2003-12-18 株式会社医薬分子設計研究所 ＮＦ−κＢ活性化阻害剤
WO2003103657A1 (ja) * 2002-06-11 2003-12-18 株式会社医薬分子設計研究所 神経変性疾患治療剤
WO2010101648A1 (en) * 2009-03-06 2010-09-10 Wood Richard D Glutamate receptor modulators and therapeutic agents
JP2011506416A (ja) * 2007-12-13 2011-03-03 ユニバーシティ オブ ダンディー 医療用シグマリガンド及びＩＫＫ／ＮＦ−κＢ阻害剤
JP2015520151A (ja) * 2012-05-08 2015-07-16 エアロミクス・リミテッド・ライアビリティ・カンパニーＡｅｒｏｍｉｃｓ，ＬＬＣ 新規方法

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE615511A (enExample) 1961-03-25
NL292958A (enExample) 1962-05-29 1900-01-01
GB8809205D0 (en) 1988-04-19 1988-05-25 Nye P C G Treatment of oedema
US5137871A (en) 1989-07-28 1992-08-11 Regents Of The University Of California Treatment to reduce edema for brain and musculature injuries
DE4010536A1 (de) * 1990-04-02 1991-10-10 Boehringer Mannheim Gmbh Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure
US5486530A (en) 1991-04-27 1996-01-23 Boehringer Mannheim Gmbh Use of torasemide for the treatment of brain oedemas
DE4113820A1 (de) 1991-04-27 1992-10-29 Boehringer Mannheim Gmbh Verwendung von torasemid zur behandlung von hirnoedemen
US5741671A (en) 1991-12-12 1998-04-21 The Johns Hopkins University Isolation cloning and expression of transmembrane water channel aquaporin 1(AQP1)
US5858702A (en) 1991-12-13 1999-01-12 The Johns Hopkins University Isolation, cloning and expression of transmembrane water channel Aquaporin 5 (AQP5)
US5519035A (en) 1993-07-02 1996-05-21 Cornell Research Foundation, Inc. Treatment of stroke or in anticipation of the occurrence of brain ischemia
US20060167110A1 (en) 1995-01-13 2006-07-27 Blume Cherly D Methods for treating cerebrovascular disease by administering desmethylselegiline
US6391303B1 (en) 1996-11-18 2002-05-21 Emisphere Technologies, Inc. Methods and compositions for inducing oral tolerance in mammals
US6255298B1 (en) 1997-08-06 2001-07-03 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases
US5905090A (en) 1998-04-29 1999-05-18 Italfarmaco S.P.A. Analogues of the active metabolite of leflunomide
CO5180581A1 (es) 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
US6500809B1 (en) 1999-11-12 2002-12-31 Neuron Therapeutics, Inc. Hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema therewith
ATE257479T1 (de) 1999-12-10 2004-01-15 Pfizer 5-ring heteroarylsubstituierte 1,4- dihydropyridine als bradykinin antagonisten
AU2002222683B9 (en) 2000-12-18 2021-12-23 Institute Of Medicinal Molecular Design, Inc Inflammatory cytokine release inhibitor
EP2438913B1 (en) 2002-03-20 2020-05-06 University of Maryland, Baltimore A non-selective cation channel in neural cells and compounds that block the channel for use in treating brain swelling
US8980952B2 (en) 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
CN1658854A (zh) 2002-06-05 2005-08-24 株式会社医药分子设计研究所 免疫关联蛋白激酶抑制剂
TW200410671A (en) 2002-06-05 2004-07-01 Inst Med Molecular Design Inc Medicines for inhibiting the activation of AP-1
EP1510207A4 (en) 2002-06-05 2008-12-31 Inst Med Molecular Design Inc THERAPEUTIC MEDICAMENT AGAINST DIABETES
WO2003103665A1 (ja) 2002-06-06 2003-12-18 株式会社医薬分子設計研究所 抗アレルギー薬
US20060014811A1 (en) 2002-06-10 2006-01-19 Susumu Muto Medicament for treatment of cancer
EP1542699A4 (en) 2002-07-15 2009-03-25 Myriad Genetics Inc COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
ES2398460T3 (es) 2003-02-06 2013-03-19 Queen's University Of Belfast Péptido antagonista del receptor B2 de bradiquinina proveniente de la piel de un anfibio
EA013846B1 (ru) 2003-05-01 2010-08-30 Инноджен Калбиотех Пте Лтд. Фармацевтическая композиция, содержащая лактат, и ее применение
US20070042997A1 (en) 2003-07-16 2007-02-22 Akiko Itai Medicament for treatment of dermal pigmentation
JP2007509044A (ja) 2003-10-08 2007-04-12 バーテックス　ファーマシューティカルズ　インコーポレイテッド シクロアルキルピラニル基を含むａｔｐ結合カセットトランスポーターのモジュレータ
US8467876B2 (en) 2003-10-15 2013-06-18 Rmx, Llc Breathing disorder detection and therapy delivery device and method
JPWO2005039556A1 (ja) 2003-10-29 2007-02-15 紘一 首藤 血行再建術後の再狭窄又は再閉塞の治療及び／又は予防のための医薬
EP1691817A2 (en) 2003-12-02 2006-08-23 Corgentech, Inc. NF-kB OLIGONUCLEOTIDE DECOY MOLECULES
CN101043891A (zh) 2004-09-18 2007-09-26 巴尔的摩马里兰大学 靶向NCCa－ATP通道的治疗剂及其使用方法
AU2005287090A1 (en) 2004-09-18 2006-03-30 Department Of Veterans Affairs Therapeutic agents targeting the NCca-ATP channel and methods of use thereof
US7601745B2 (en) 2004-09-27 2009-10-13 4Sc Ag Heterocyclic NF-kB inhibitors
MX2007008159A (es) 2005-01-04 2007-10-11 Novartis Ag Biomarcadores para identificar la eficacia del tegaserod en pacientes con constipacion cronica.
MY147790A (en) 2005-04-28 2013-01-31 Takeda Pharmaceutical Stable emulsion composition
WO2007084464A2 (en) 2006-01-17 2007-07-26 The University Of North Carolina At Chapel Hill Water channel blockers and methods of use thereof
JP4273235B2 (ja) 2006-06-01 2009-06-03 国立大学法人 新潟大学 アクアポリン４阻害薬
WO2008060705A2 (en) 2006-06-06 2008-05-22 Genentech, Inc. Anti-dll4 antibodies and methods using same
RU2008152435A (ru) 2006-06-06 2010-07-20 Дженентек, Инк. (Us) Композиции и способы регулирования развития сосудов
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
US10004703B2 (en) 2006-10-12 2018-06-26 Biogen Chesapeake Llc Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels
WO2008046014A1 (en) 2006-10-12 2008-04-17 Remedy Pharmaceuticals, Inc. Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors
CA2669117A1 (en) 2006-10-26 2008-05-02 Gary A. Flynn Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
US9316633B2 (en) 2006-11-16 2016-04-19 The Regents Of The University Of California Methods for identifying inhibitors of solute transporters
WO2008067373A2 (en) 2006-11-28 2008-06-05 Alcon Research, Ltd. RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS
WO2008067382A2 (en) 2006-11-28 2008-06-05 Alcon Research, Ltd. Rnai-mediated inhibition of aquaporin 4 for treatment of iop-related conditions
WO2008089103A2 (en) 2007-01-12 2008-07-24 University Of Maryland, Baltimore Targeting ncca-atp channel for organ protection following ischemic episode
TWI629058B (zh) 2007-01-16 2018-07-11 陳建宏 醫藥組成物及其用途
US20120183600A1 (en) 2007-01-16 2012-07-19 Chien-Hung Chen Novel composition for treating metabolic syndrome and other conditions
CA2618099C (en) 2007-02-09 2016-09-20 University Of Maryland, Baltimore Antagonists of a non-selective cation channel in neural cells
CA2678486C (en) 2007-02-17 2019-03-12 President And Fellows Of Harvard College Compositions and method for tissue preservation
WO2008133884A2 (en) 2007-04-23 2008-11-06 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
CA3065983C (en) 2007-06-22 2022-07-26 The United States Of America As Represented By The Department Of Veterans Affairs Inhibitors of ncca-atp channels for therapy
WO2009006555A2 (en) 2007-07-02 2009-01-08 Yu, Ming Methods, composition, targets for combinational cancer treatments
CN102872020A (zh) * 2007-10-23 2013-01-16 株式会社医药分子设计研究所 Pai-1产生抑制剂
US20090239868A1 (en) 2007-10-23 2009-09-24 Institute Of Medical Molecular Design, Inc. Inhibitor of pai-1 production
EP2868315B1 (en) 2007-12-04 2017-05-31 Remedy Pharmaceuticals, Inc. Improved formulations and methods for lyophilization and lyophilates provided thereby
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20110034560A1 (en) 2008-01-29 2011-02-10 Sven Jacobson Liquid formulations of compounds active at sulfonylurea receptors
WO2009139925A1 (en) 2008-05-16 2009-11-19 Panacea Pharmaceuticals, Inc. Methods for the treatment of brain edema
EP2719380A3 (en) 2008-09-16 2014-07-30 University of Maryland, Baltimore SUR1 inhibitors for therapy
US20120010178A1 (en) 2008-10-21 2012-01-12 President And Fellows Of Harvard College Methods and compounds for treatment of neurodegenerative disorders
GB0823366D0 (en) 2008-12-22 2009-01-28 Uni I Oslo Synthesis
CN102348668B (zh) 2009-01-12 2014-11-19 培力有限公司 化合物及其用于治疗炎症和调节免疫应答的用途
WO2010096627A1 (en) 2009-02-20 2010-08-26 Lisanti Michael P Therapeutics and methods for treating neoplastic diseases comprising determining the level of caveolin-1 and/or caveolin-2 in a stromal cell sample
RU2564900C2 (ru) 2010-03-10 2015-10-10 Дзе Юниверсити Оф Флорида Рисерч Фаундейшн, Инк. Модулирование аквапоринов релаксином
KR20230165363A (ko) 2010-07-19 2023-12-05 바이오젠 체사피크 엘엘씨 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
EP2598145A1 (en) * 2010-07-28 2013-06-05 Boehringer Ingelheim International GmbH Pharmaceutical composition for treatment of respiratory and inflammatory diseases
US20110052678A1 (en) 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
US20120238623A1 (en) 2011-03-14 2012-09-20 Chandraratna Roshantha A Inflammation and Autoimmune Disorder Treatment using RARa Selective Agonists
US9290765B2 (en) 2011-05-02 2016-03-22 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg Protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase abl-related gene (ARG)
RU2461375C1 (ru) * 2011-05-19 2012-09-20 Учреждение Российской академии медицинских наук Научно-исследовательский институт онкологии Сибирского отделения Российской академии медицинских наук (НИИ онкологии СО РАМН) Способ комбинированного лечения больных местно-распространенным раком желудка
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
US9452973B2 (en) 2012-05-04 2016-09-27 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Modulators of the relaxin receptor 1
CN105636583B (zh) 2013-09-13 2019-08-20 板井昭子 水溶液制剂及其制造方法
RU2691951C2 (ru) 2013-11-06 2019-06-19 Аэромикс, Инк. Новые составы
US9163042B2 (en) 2013-12-13 2015-10-20 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
CN107207417A (zh) 2014-11-13 2017-09-26 埃罗米克斯公司 新方法
MA45307A (fr) 2015-05-29 2018-04-11 Biogen Chesapeake Llc Procédés de réduction ou de prévention des dommages à l'intima provoqués par une stimulation mécanique de cellules endothéliales
CN108348534A (zh) 2015-10-07 2018-07-31 生物切萨皮克有限责任公司 治疗与cns水肿相关的损伤或状况的方法
AU2017261828B2 (en) 2016-05-13 2023-04-13 Aeromics, Inc. Crystals
EP4483955A3 (en) 2016-07-29 2025-03-12 Remedy Pharmaceuticals, Inc. Methods of medical treatment with sur1-trpm4 channel inhibitors
MX2023001493A (es) 2020-08-05 2023-06-23 Jiangsu Simcere Pharm Co Ltd Composicion farmaceutica de un inhibidor de la acuaporina y metodo para la preparacion de la misma.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003103656A1 (ja) * 2002-06-06 2003-12-18 株式会社医薬分子設計研究所 Ｏ−置換ヒドロキシアリール誘導体
WO2003103654A1 (ja) * 2002-06-10 2003-12-18 株式会社医薬分子設計研究所 ＮＦ−κＢ活性化阻害剤
WO2003103657A1 (ja) * 2002-06-11 2003-12-18 株式会社医薬分子設計研究所 神経変性疾患治療剤
JP2011506416A (ja) * 2007-12-13 2011-03-03 ユニバーシティ オブ ダンディー 医療用シグマリガンド及びＩＫＫ／ＮＦ−κＢ阻害剤
WO2010101648A1 (en) * 2009-03-06 2010-09-10 Wood Richard D Glutamate receptor modulators and therapeutic agents
JP2015520151A (ja) * 2012-05-08 2015-07-16 エアロミクス・リミテッド・ライアビリティ・カンパニーＡｅｒｏｍｉｃｓ，ＬＬＣ 新規方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021023226A (ja) * 2019-08-06 2021-02-22 学校法人慶應義塾 アクアポリン活性調節剤候補のハイスループットスクリーニング方法

Also Published As

Publication number Publication date
HK1224228A1 (zh) 2017-08-18
US20220143048A1 (en) 2022-05-12
EP3065729A2 (en) 2016-09-14
US20210275549A1 (en) 2021-09-09
EP3065728A4 (en) 2017-06-07
CN106163506A (zh) 2016-11-23
EP3065727A1 (en) 2016-09-14
CN112402434A (zh) 2021-02-26
US12496308B2 (en) 2025-12-16
MX2021008629A (es) 2021-08-19
US11071744B2 (en) 2021-07-27
ES2834131T3 (es) 2021-06-16
CA2929821A1 (en) 2015-05-14
US9949991B2 (en) 2018-04-24
IL245420A0 (en) 2016-06-30
EP3065727B1 (en) 2020-08-26
US11801254B2 (en) 2023-10-31
US10258636B2 (en) 2019-04-16
MX386250B (es) 2025-03-18
JP2022003084A (ja) 2022-01-11
EP3065727A4 (en) 2017-05-31
US20160279155A1 (en) 2016-09-29
US20160346302A1 (en) 2016-12-01
US20240299425A1 (en) 2024-09-12
AU2014346682B2 (en) 2020-03-12
JP6535338B2 (ja) 2019-06-26
WO2015069956A3 (en) 2015-11-12
WO2015069948A1 (en) 2015-05-14
MX2016006012A (es) 2016-12-09
RU2016121850A3 (enExample) 2018-08-08
AU2020203697A1 (en) 2020-06-25
JP2019163314A (ja) 2019-09-26
US9827253B2 (en) 2017-11-28
JP2016536370A (ja) 2016-11-24
US20160264604A1 (en) 2016-09-15
US20180169118A1 (en) 2018-06-21
JP6957557B2 (ja) 2021-11-02
EP3065728A1 (en) 2016-09-14
US20190307779A1 (en) 2019-10-10
RU2691951C2 (ru) 2019-06-19
US20200297740A1 (en) 2020-09-24
RU2016121850A (ru) 2017-12-08
EP3065729A4 (en) 2017-05-31
US10894055B2 (en) 2021-01-19
AU2014346682A1 (en) 2016-06-09
US12213987B2 (en) 2025-02-04
CN112370456A (zh) 2021-02-19
KR20160079109A (ko) 2016-07-05
SG11201604153UA (en) 2016-07-28
IL245420B (en) 2020-10-29
WO2015069961A1 (en) 2015-05-14
WO2015069956A2 (en) 2015-05-14
BR112016010338A2 (pt) 2017-08-08

Similar Documents

Publication Publication Date Title
JP6570597B2 (ja) 新規方法
JP2016535787A (ja) 新規方法
CN104869993B (zh) 治疗阿尔茨海默病及相关疾病的组合疗法
JP2013528198A (ja) １型糖尿病の処置
EP2882431B1 (en) Probenecid for treating decompensated heart failure
HK1208363B (en) Compounds for use in the treatment of aquaporin-mediated diseases
HK40053435A (en) Probenecid for treating decompensated heart failure

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180828

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181210

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190402

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20190827